Reproductive endocrinology and clinical aspects of obesity in women.
Obesity is a growing worldwide problem and is associated with a wide range of adverse effects on the female reproductive system. The endocrinological changes in obesity that may cause these adverse effects are complex and include changes in circulating adipokines and sex steroids as well as insulin resistance. Considerable evidence suggests an adverse effect of obesity on the risk of miscarriage and other maternal and fetal complications. Obese patients are also more prone to infertility. The most important single method to improve reproductive performance in obese women is weight loss that can be achieved with lifestyle changes and diet. Antiobesity drugs may also be used and, in severe cases, bariatric surgery.
Metwally
Mostafa
M
The Academic Unit of Reproductive and Developmental Medicine, The University of Sheffield and Sheffield Teaching Hospitals,Sheffield, S10 4ED, UK. m.metwally@sheffield.ac.uk
Ledger
William L
WL
Li
Tin Chiu
TC
D000022:Abortion, Spontaneous / Q000209:etiology; D052242:Adiponectin / Q000378:metabolism; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D050110:Bariatric Surgery; D004704:Endocrinology / Q000379:methods*; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D054439:Ghrelin / Q000096:biosynthesis; D006801:Humans; D007247:Infertility, Female / Q000150:complications* / Q000188:drug therapy; D020738:Leptin / Q000378:metabolism; D009765:Obesity / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D011247:Pregnancy; D052243:Resistin / Q000096:biosynthesis; D012306:Risk
D052242:Adiponectin; D019440:Anti-Obesity Agents; D054439:Ghrelin; D020738:Leptin; D052243:Resistin